Trial is approved for stem cell treatment for dry AMD

02/3/2012 | Wall Street Journal, The

The FDA is permitting StemCells to conduct a safety and efficacy trial of therapeutic candidate HuCNS-SC cells among patients with dry age-related macular degeneration, or AMD. Last year, testing of the adult stem cell treatment for a rare childhood brain disorder was halted because of a lack of qualified participants.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD